annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 40F Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in
pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture
mass spectrometry. (Abstract #9528)
E. Petricoin, M. M. Ross, W. Zhou, D. Tamburro, A. Luchini, L. A. Liotta,
R. E. Scully, T. L. Miller, S. E. Sallan, S. E. Lipshultz
Brd. 40G A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral
selective small molecule inhibitor of Aurora A kinase: A Children’s Oncology
Group Phase I Consortium study. (Abstract #9529)
Y. P. Mosse, E. G. Lipsitz, J. M. Maris, B. Weigel, P. C. Adamson, M. Ingle,
C. H. Ahern, S. Blaney
Brd. 40H A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF
Trap): A Children’s Oncology Group Phase I Consortium study. (Abstract
#9530)
J. R. Park, D. S. Hawkins, M. Ingle, S. C. Borinstein, J. L. Glade Bender,
D. Yamashiro, S. Baruchel, A. P. Chen, P. C. Adamson, S. Blaney
Brd. 41A A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573,
MK-8669) in patients (pts) with refractory solid tumors. (Abstract #9531)
L. Gore, T. M. Trippett, H. M. Katzenstein, J. L. Boklan, A. Narendaren, A. Smith,
M. Macy, N. Narasimhan, C. D. Turner, M. L. Nieder
Brd. 41B Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A
New Approach to Neuroblastoma Therapy (NANT) Consortium study.
(Abstract #9532)
J. E. Minturn, J. Villablanca, G. A. Yanik, J. R. Park, S. G. Groshen, E. T. Hellriegel,
D. Bensen-Kennedy, K. K. Matthay, G. M. Brodeur, J. M. Maris
Brd. 41C Phase II window of irinotecan � carboplatin in newly diagnosed patients with
rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center
(MSKCC) Protocol IRB 03–099. (Abstract #9533)
L. H. Wexler, S. L. Wolden, S. J. Abramson, A. Price, S. Karimi, M. P. La Quaglia,
A. J. Chou, P. R. Merola, P. A. Meyers
Brd. 41D Cisplatin plus pirarubicin chemotherapy and combination ifomide,
etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma.
(Abstract #9534)
E. Hiyama, A. Kamimatsuse, N. Kamei, K. Watanabe, T. Hishiki, T. Tajiri, K. Ida,
M. Yano, S. Kondo, F. Sasaki, Japanese Study Group for Pediatric Liver Tumor
Brd. 41E Phase II trial of pemetrexed in children with refractory solid tumors: A
Children’s Oncology Group study. (Abstract #9535)
A. B. Warwick, S. Malempati, M. D. Krailo, A. S. Melemed, P. C. Adamson,
S. Blaney
Brd. 41F Safety, kinetics, and outcome following rituximab (R) in combination with
FAB chemotherapy in children and adolescents (C�A) with stage III/IV
(Group B) and BM�/CNS� (Group C) mature b-NHL: A Children’s Oncology
Group report. (Abstract #9536)
M. S. Cairo, J. C. Lynch, L. Harrison, S. L. Perkins, B. Shiramizu, T. G. Gross,
W. Sanger, S. Goldman
Brd. 41G A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric
patients with refractory/recurrent Hodgkin Disease (HD): A Children’s
Oncology Group (COG) study. (Abstract #9537)
T. M. Horton, R. A. Drachtman, L. Chen, T. M. Trippett, P. De Alarcon, A. R. Chen,
R. P. Guillerman, K. McCarten, S. M. Hogan, C. L. Schwartz
Brd. 41H Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling
interference in Ewing’s sarcoma (ES). (Abstract #9538)
A. C. van de Luijtgaarden, Y. M. Versleijen-Jonkers, M. H. Roeffen, U. E. Flucke,
B. W. Schreuder, W. T. Graaf
254